Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past

Thierry Burnouf, Lassina Barro, Ouada Nebie, Yu Wen Wu, Hadi Goubran, Folke Knutson, Jerard Seghatchian

研究成果: 雜誌貢獻回顧型文獻

2 引文 (Scopus)

摘要

Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients, suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible, but avoidable, side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.

原文英語
文章編號102674
期刊Transfusion and Apheresis Science
58
發行號6
DOIs
出版狀態已發佈 - 十二月 2019

指紋

Regenerative Medicine
Cell- and Tissue-Based Therapy
Blood Platelets
Safety
Inborn Genetic Diseases
Malpractice
Intercellular Signaling Peptides and Proteins
Industry
Pathology
Viruses

ASJC Scopus subject areas

  • Hematology

引用此文

Viral safety of human platelet lysate for cell therapy and regenerative medicine : Moving forward, yes, but without forgetting the past. / Burnouf, Thierry; Barro, Lassina; Nebie, Ouada; Wu, Yu Wen; Goubran, Hadi; Knutson, Folke; Seghatchian, Jerard.

於: Transfusion and Apheresis Science, 卷 58, 編號 6, 102674, 12.2019.

研究成果: 雜誌貢獻回顧型文獻

@article{15c2dc6cca1f4ae391be5c46d738ac58,
title = "Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past",
abstract = "Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients, suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible, but avoidable, side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.",
keywords = "HPL, Human platelet lysate, Safety, Virus",
author = "Thierry Burnouf and Lassina Barro and Ouada Nebie and Wu, {Yu Wen} and Hadi Goubran and Folke Knutson and Jerard Seghatchian",
year = "2019",
month = "12",
doi = "10.1016/j.transci.2019.102674",
language = "English",
volume = "58",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Viral safety of human platelet lysate for cell therapy and regenerative medicine

T2 - Moving forward, yes, but without forgetting the past

AU - Burnouf, Thierry

AU - Barro, Lassina

AU - Nebie, Ouada

AU - Wu, Yu Wen

AU - Goubran, Hadi

AU - Knutson, Folke

AU - Seghatchian, Jerard

PY - 2019/12

Y1 - 2019/12

N2 - Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients, suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible, but avoidable, side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.

AB - Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients, suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible, but avoidable, side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.

KW - HPL

KW - Human platelet lysate

KW - Safety

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=85075359091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075359091&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2019.102674

DO - 10.1016/j.transci.2019.102674

M3 - Review article

C2 - 31735652

AN - SCOPUS:85075359091

VL - 58

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 6

M1 - 102674

ER -